Detail akcie Grifols Depository Receipt online

Business Summary: Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Grifols SA - ADR revenues increased 7% to EUR3.44B. Net income totaled EUR36.3M vs. loss of EUR70.1M. Revenues reflect Bioscience segment increase of 8% to EUR2.92B, Bio Supplies segment increase of 33% to EUR109.6M, Rest of the World segment increase of 15% to EUR773M, European Union segment increase of 13% to EUR505.4M. Net Income reflects Selling/General/Admin.